INTERFERON ALPHA-2A IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE - RESULTS OF THE SPANISH GROUP

被引：10

作者：

FERNANDEZRANADA, JM

LAVILLA, E

ODRIOZOLA, J

GARCIALARANA, J

LOZANO, M

PARODY, R

GIRALDO, MP

CARBONELL, F

FERRO, MT

STEEGMANN, JL

机构：

[1] Hospital de la Princesa, Madrid

[2] Hospital Ramón y Cajal, Madrid

[3] Hospital Severo Ochoa, Madrid

[4] Hospital Clinico Universitario, Sevilla

[5] Hospital Miguel Servet, Zaragoza

[6] Hospital General Universitario, Valencia

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; INTERFERON-ALPHA; HYDROXYUREA; HYPERTRIGLYCERIDEMIA;

D O I：

10.3109/10428199309047882

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fifty-one patients with CML in chronic phase, less than two years after diagnosis, were included in one multicentric study aiming to assess the therapeutic value of interferon alpha 2a (IFN alpha2a) in this setting. The therapeutic scheme was biphasic: The patients were first treated with hydroxyurea, and afterwards only received IFN alpha2a, at a planned dose of 5MU/m2/day, s.c. Thirty-eight patients (81%) achieved an hematologic response, which was complete in 57% of the total group. The median time to response was of 42 days. In the last evaluation, a complete hematologic response was sustained in 21 patients (47%). Philadelphia suppression was obtained in 44% of the patients who achieved hematologic responses; major cytogenetic responses were obtained in 16% of the patients. The patients who obtained genetic responses were significantly younger and had a shorter interval from diagnosis to IFN than the patients who did not respond. At the moment of evaluation, 90% of the patients are alive, but the median follow-up of the series (217 days, range 21-1150) is too short to analyze any impact of IFN over survival. Six patients (12%) discontinued IFN because of toxicity, three of them because of severe flu-like syndrome. Leukopenia and thrombocytopenia were frequent, but rarely severe. Hypertriglyceridemia has been a very frequent finding.

引用

页码：175 / 179

页数：5

共 9 条

[1]

Talpaz M., McCredie K., Mauligit G.M., Gutterman J.U., Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia, Blood, 62, pp. 689-692, (1983)

[2]

Talpaz M., Kantarjian H.M., McCredie K.B., Trujillo J.M., Keating M.J., Gutterman J.U., Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha 2a in chronic myelogenous leukemia, N. Eng. J. Med., 316, pp. 1065-1069, (1986)

[3]

Talpaz M., Kantarjian H.M., McCredie K.B., Keating M.J., Trujillo J., Gutterman J.U., Clinical investigation of human alpha interferon in chronic myelogenous leukemia, Blood, 69, pp. 1280-1288, (1987)

[4]

Alimena G., Morra E., Lazzarino M., Liberati A.M., Montefusco E., Inverardi D., Bernasconi P., Mancini M., Donti E., Grignani F., Bernasconi C., Dianzani F., Mandelli F., Interferon alpha-2b as therapy for Philadelphia-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration, Blood, 72, pp. 642-647, (1988)

[5]

Freund M., von Wussow P., Diedrich H., Elsert R., Link H., Wilke H., Buchholz F., LeBlanc S., Fonatsch C., Deicher H., Poliwoda H., Recombinant human interferon alpha 2b in chronic myelogenous leukemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies, Br. J. Haematol., 72, pp. 350-356, (1989)

[6]

Talpaz M., Kantarjian H., Kurzrock R., Trujillo J.M., Gutterman J.U., Interferon alpha produces sustained cytogenetic response in chronic myelogenous leukemia, Ann. Int. Med., 114, pp. 532-538, (1991)

[7]

Kantarjian H.M., Keating M.J., Smith T.L., Talpaz M., McCredie K.B., Proposals for a simple synthesis prognostic staging system in chronic myelogenous leukemia, Am. J. Med., 88, 1, pp. 532-538, (1990)

[8]

Odriozola J., Steegmann J.L., Rodriguez J.M., Giralt M., Alegre A., Castillo S., Marron A., Fernandez-Ranada J.M., Freund, Et al., Interferon alpha 2a in the treatment of chronic myeloid leukemia. Results of the Spanish Group on Interferon alpha 2a in CML, (1992)

[9]

Grunfeld C., Kotler D.P., Shigenaga J.K., Doerrler W., Tierney A., Wang J., Pierson R.N., Feingold K.R., Circulatory interferon alpha levels and hypertriglyceridemia in the Acquired Immunodeficiency Syndrome, Am. J. Med., 90, pp. 154-162, (1991)

← 1 →